MP13 Community initiation of clozapine in adults


Category
Medicine management
Code
MP13
Issue No
3

Target Audience

All clinical staff working in community settings in particular CMHTS, Crisis and Home Treatment Teams

Purpose

Clozapine has side effects which need to be monitored and the dose is carefully titrated to reduce the risk and adverse effects. This document sets out the rationale for initiation in the community so that the patient receives the same level of monitoring and assessment as they would if initiated as an inpatient. It also highlights the inclusion and exclusion criteria for suitable candidates. Covers re-titration in the community if doses are missed.

Origin

Lead executive
Medical Director

Author and contact number
Chief Pharmacist
01244 397379


Policy dates & history

Implementation Date

30 June 2011

Review Date

30 June 2016

Approval Meeting

Medicines Management Group (MMG)

Ratification

Document Quality Group (DQG)

Download

MP13 Community initiation of clozapine Issue 3.pdf

0.10MB
Download Now
Text size A- A+
Contrast options